Lion Group Holding Reaffirms Long-Term HYPE Holdings With $15.8 Million Position

Lion Group Holding Ltd. (Nasdaq: LGHL) said it entered a non-binding memorandum of understanding with U.S.-headquartered Aquila Hash, Inc. to acquire 100% of its shares. The deal terms will be set in future definitive agreements, subject to due diligence and customary closing conditions. Aquila Hash develops and operates AI factories, GPU cloud platforms, and related infrastructure services.

Lion Group Holding Ltd. (NASDAQ: LGHL) said it signed a non-binding memorandum of understanding with U.S.-headquartered Aquila Hash, Inc. to acquire 100% of Aquila Hash’s shares. The deal terms are to be set in definitive agreements, subject to due diligence and customary closing conditions. Aquila Hash develops and operates AI Factories and GPU cloud infrastructure.

Zealand Pharma reported that Boehringer Ingelheim's survodutide achieved co-primary endpoints in its Phase III trial, with participants experiencing up to 13.1% weight loss compared to 3.1% for placebo over 76 weeks. The drug also improved glycemic control in adults with obesity or type 2 diabetes, according to the company.

Sanofi (SASY) shares rose 1.4% to €73.65 after announcing an $8B collaboration with Regeneron to co-develop and co-commercialize four new antibodies. The deal includes a $1B upfront payment and up to $7B in milestone payments. Analysts have a Buy rating and a 12-month price target of €94.06, suggesting significant upside from current levels.

Stifel upgraded Hub Group (HUBG) to Hold from Sell with a $29.00 price target. The stock trades near its 52-week low at $29.58, down 29.86% YTD. Stifel cites improved risk/reward balance due to the price decline, despite accounting issues and earnings uncertainty. UBS maintains a Neutral rating with a $38.00 target. Hub Group faces accounting challenges and a leadership change.

FrontView REIT, Inc.'s average stock price target was reduced from $22.42 to $22.29 by 12 analysts, with a range of $19 to $24. This implies a 34% upside from the Sep. 30 closing price. The consensus rating remains 'Buy' with 9 Buys, 2 Holds, and 1 Sell.